Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
Asset disposition
Acq. announced
|
|
NEKTAR THERAPEUTICS (NKTR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/15/2023 |
4
| WHITFIELD ROY A (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 30,000 shares
@ $0.57, valued at
$17.1k
|
|
| 05/17/2023 |
4
| Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 9,791 shares
@ $0.72, valued at
$7k
|
|
| 05/17/2023 |
4
| Wilson Mark Andrew (Chief Legal Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 7,543 shares
@ $0.72, valued at
$5.4k
|
|
| 05/17/2023 |
4
| ROBIN HOWARD W (President & CEO) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 20,361 shares
@ $0.72, valued at
$14.7k
|
|
| 11/18/2022 |
4
| Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 13,460 shares
@ $3.57, valued at
$48.1k
|
|
| 11/18/2022 |
4
| Wilson Mark Andrew (Chief Legal Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 8,690 shares
@ $3.57, valued at
$31k
|
|
| 11/18/2022 |
4
| Thomsen Jillian B. (CFO) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 11,095 shares
@ $3.57, valued at
$39.6k
|
|
| 11/18/2022 |
4
| ROBIN HOWARD W (President & CEO) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 38,014 shares
@ $3.57, valued at
$135.7k
|
|
| 09/26/2022 |
4
| Curet Myriam (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 4,198 shares
@ $3.16, valued at
$13.3k
|
|
| 09/26/2022 |
4
| Ajer Jeffrey Robert (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 4,198 shares
@ $3.16, valued at
$13.3k
|
|
| 09/26/2022 |
4
| CHESS ROBERT (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 5,100 shares
@ $3.19, valued at
$16.3k
|
|
| 09/20/2022 |
4
| WHITFIELD ROY A (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/20/2022 |
4
| GREER R SCOTT (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/20/2022 |
4
| EASTHAM KARIN (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/20/2022 |
4
| Curet Myriam (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/20/2022 |
4
| CHESS ROBERT (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/20/2022 |
4
| Brainard Diana (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/20/2022 |
4
| Ajer Jeffrey Robert (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,200 shares
@ $0
Granted 20,400 options
@ $3.47, valued at
$70.8k
|
|
| 09/14/2022 |
4
| EASTHAM KARIN (Director) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 21,267 shares
@ $3.61, valued at
$76.8k
|
|
| 08/19/2022 |
4
| Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 73,716 shares
@ $4.65, valued at
$342.8k
|
|
| 08/17/2022 |
4
| Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 135,000 shares
@ $0
Sold 10,560 shares
@ $4.76, valued at
$50.3k
Granted 270,000 options to buy
@ $4.91, valued at
$1.3M
|
|
| 08/17/2022 |
4
| Wilson Mark Andrew (SVP & General Counsel) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 165,938 shares
@ $0
Sold 3,189 shares
@ $4.76, valued at
$15.2k
Granted 331,875 options to buy
@ $4.91, valued at
$1.6M
|
|
| 08/17/2022 |
4
| Thomsen Jillian B. (SVP & Chief Accounting Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 165,938 shares
@ $0
Sold 2,006 shares
@ $4.76, valued at
$9.5k
Granted 331,875 options to buy
@ $4.91, valued at
$1.6M
|
|
| 08/17/2022 |
4
| ROBIN HOWARD W (President & CEO) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 410,625 shares
@ $0
Sold 13,759 shares
@ $4.76, valued at
$65.5k
Granted 821,250 options to buy
@ $4.91, valued at
$4M
|
|
| 05/17/2022 |
4
| Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 23,950 shares
@ $0
Sold 21,673 shares
@ $3.95, valued at
$85.6k
|
|
| 05/17/2022 |
4
| Wilson Mark Andrew (SVP & General Counsel) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 3,136 shares
@ $3.95, valued at
$12.4k
|
|
| 05/17/2022 |
4
| Thomsen Jillian B. (SVP & Chief Accounting Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 10,950 shares
@ $0
Sold 5,841 shares
@ $3.95, valued at
$23.1k
|
|
| 05/17/2022 |
4
| ROBIN HOWARD W (President & CEO) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 68,450 shares
@ $0
Sold 36,529 shares
@ $3.95, valued at
$144.3k
|
|
| 05/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/17/2022 |
4
| Labrucherie Gil M (SVP, COO & CFO) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Granted 28,750 shares
@ $0
Sold 17,448 shares
@ $3.95, valued at
$68.9k
|
|
| 02/18/2022 |
4
| Zalevsky Jonathan (Chief R&D Officer) has filed a Form 4 on NEKTAR THERAPEUTICS|
Txns:
| Sold 10,912 shares
@ $10.95, valued at
$119.5k
|
|
|
|
|